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Introduction
Cryopyrin-associated periodic Syndromes (CAPS) are
caused by heterozygous mutations in the NLRP3 gene.
More than 80 disease causing mutations have been iden-
tified, mostly clustered in NLRP3 exon 3, but also
described in exons 4 and 6. However, up to 50% of clini-
cally diagnosed CAPS patients (with identical clinical fea-
tures and response to anti-IL-1 treatment) show no
mutation in NLRP3 detected by conventional DNA
sequencing analysis of exons 3, 4 and 6. Recently somatic
NLRP3 mosaicism has been shown to account for up to
70% of these mutation negative CAPS patients.
Objective
To ascertain a genetic cause in a patient with a CINCA
phenotype labeled as NLRP3 mutation negative.
Methods
Massively Parallel Sequencing (MPS) and Whole Exome
Sequencing (WES) were performed on DNA extracted
from peripheral blood. WES results were confirmed by
conventional Sanger sequencing.
Case report
Twenty month old boy who presented with an urticarial-
like rash since birth. At 6 months of age he was noted to
have frontal bossing with increasing head circumference,
hepatosplenomegaly, and papilledema with no signs of
uveitis. A mild conductive hearing impairment was
detected, but no sensorineural hearing loss. Inflammatory
markers were raised with a CRP of 40mg/L.
Brain MRI showed signs of hydrocephalus and a ven-
triculo-peritoneal shun was inserted.
A clinical diagnosis of CAPS was made at this point. San-
ger sequencing of NLRP3 exons 3, 4 and 6 was consistent
with wild-type.
Over the following months his clinical status deterio-
rated with slowing development and significant failure to
thrive with growth below the 0.4th centile. Inflammatory
marks were persistently raised.
Anakinra treatment was started at 12 months of age,
resulting in a marked clinical and serological improve-
ment, with normalization of CAPS disease activity score
and inflammatory response at a dose of 3mg/kg/day.
MPS ofNLRP3 exons 3, 4 and 6 didn’t reveal any
somatic mutations. WES was then performed for the pro-
band and his parents revealing a potentially damaging het-
erozygous variant in NLRP3 exon 5 (c.G2336T; p.G779V),
which segregated with disease. Sanger sequencing of exon
5 confirmed these findings.
Conclusion
To the best of our knowledge this is the first potentially
disease associated mutation in NLRP3 exon 5. Although
we have not yet performed functional studies, in silico
prediction is consistent with a damaging role.
Our work shows that other NLRP3 exons apart from 3,
4 and 6 should be screened for germline and/or somatic
mutations in patients with a clinical diagnosis of CAPS.
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